Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.00    2.50 (5.88%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £86.34m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Placing

12 Feb 2009 16:44

RNS Number : 2541N
Iofina PLC
12 February 2009
 



Iofina plc

Placing of £5 million

12 February 2009

The Directors of Iofina plc ("Iofina" or the "Company"), the gas and iodine production and development company, are pleased to announce that the Company has conditionally raised £5 million (before expenses) through a placing of 9,090,000 new ordinary shares of 1p each in the Company (the "Placing Shares"), at a price of 55p per share (the "Placing"). 

The net proceeds of the Placing will be primarily applied to pursue several new opportunities in the iodine derivatives market that have recently emerged. If entered into, the Directors believe the ensuing vertical integration through both production and derivatives should result in significantly better margins.

The Placing Shares will be subscribed for by certain new and existing institutional shareholders of the Company. The Placing is conditional, inter alia, on admission of the Placing Shares to trading on AIM ("Admission").

The Placing Shares will represent 8.83 per cent. of the then enlarged issued share capital of the Company immediately following Admission.  The number of ordinary shares of 1p each ("Ordinary Shares") in issue following the Placing, and the total number of voting rights, will be 102,906,114. The Placing Shares will rank pari passu with existing Ordinary Shares. Application will be made for Admission which is expected to take place on 18 February 2009.

David Schneider, Chief Executive, commented: "Despite extremely difficult capital market conditions, we have been delighted by the response of both new and existing institutional investors who share our excitement and vision with respect to vertically integrating Iofina into the iodine derivatives market The Placing was done at a 12% premium to the previous day's closing price.

With approximately £17m of net cash on the balance sheet on completion of the Placing, Iofina will be fully funded both to progress the Altantis prospect through to full development and positive cash flow generation, while at the same time move Iofina Chemical into the iodine derivatives market. This move will enhance Iofina's strategic position in the US where the large domestic blue chip end users of iodine derivatives currently rely heavily on imports from Chile and Japan. We continue to remain excited about Iofina's prospects and our ability to create value for our shareholders.

For further information, please contact: 

Lance Baller

Iofina plc

Tel: +44(0)20 3006 3135 x301

 

Nominated Adviser:

James Harris/Angela Peace

Strand Partners Limited

Tel: +44(0)20 7409 3494

 

Broker:

Rory Scott

Mirabaud Securities Limited

Tel: +44(0)20 7878 3360

 

Media Contact:

Chelsea Hayes

Pelham Public Relations

Tel: +44 (0)20 7743 6675

 

About Iofina

Iofina is involved in the exploration and production of both iodine and natural gas which have been discovered on acreages which the Company holds. The presence of both iodine and natural gas allows the Iofina group of companies (the "Group") to generate dual revenue streams over a single cost structure. The dual revenue approach has worked successfully in the Mobara field in Japan which has been producing iodine and natural gas for over the past 50 years. Iodine is a rare element that is only produced in a few countries in the world with over 79 per cent. coming from Chile (58 per cent.) and Japan (21 per cent.). This has resulted in the US and Western Europe becoming major net importers to meet growing demands from pharmaceutical and industrial manufacturers. Iodine demand is growing at 6.6 per cent. per annum driven by a combination of increased usage in a wide variety of sectors from pharmaceutical manufacturing, LCD screen manufacturing, medical imaging, cosmetics, biocides in paints and pesticides, as well as the emergence of new uses for iodine and greater consumption from developing countries such as India and China. The Group's proprietary Wellhead Extraction Technology® method will allow low cost production metrics and high operational efficiencies compared to other large iodine/gas fields in MobaraJapan and OklahomaUSA. Iofina owns a thirteen mile pipeline that ultimately links to the TransCanada pipeline. Iofina currently has leased over 60,000 net acres in the Atlantis Prospect and approximately 30,000 net acres in its Triton Prospect. MHA Petroleum Consultants, Inc., the Competent Person, estimates that as of 1 February 2008 and, based on Iofina's core c.28,000 acres at that time in the Atlantis Prospect, Iofina has 100.6 million kg of iodine in place and has 155.6Bcf of natural gas in place, making the Atlantis Prospect the largest known iodine resource in North America. The directors of the Company believe that Iofina's low cost development strategy and its dual revenue streams are expected to provide both excellent margins and reduced revenue volatility since the two product streams are unrelated relative to their respective markets.

Iofina is traded on the London Stock Exchange's AIM Market under the ticker: IOF. 

www.iofina.com 

Wellhead Extraction Technology® and WET® are registered trademarks of Iofina Natural Gas, Inc.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROIDGGMZVZZGLZM
Date   Source Headline
2nd Oct 20132:40 pmRNSHolding(s) in Company
26th Sep 20133:32 pmRNSHolding(s) in Company
25th Sep 20137:00 amRNSHalf Yearly Report
19th Sep 20137:00 amRNSDirectorate Change
6th Sep 20137:00 amRNSNotice of Results
16th Aug 20137:00 amRNSBoard Appointment
2nd Aug 20138:30 amRNSIOSorb Patent Awarded
1st Aug 20137:00 amRNSOperational Update
4th Jul 20138:56 amRNSDirector/PDMR Shareholding
3rd Jul 20135:40 pmRNSChange of Registered Office
28th Jun 20132:05 pmRNSDirector/PDMR Shareholding
25th Jun 20138:15 amRNSProduction & Produced Water Congress 2013
24th Jun 20132:22 pmRNSHolding(s) in Company
24th Jun 201312:00 pmRNSResponse to Share Price Movement
19th Jun 20132:10 pmRNSResult of AGM
19th Jun 20137:00 amRNSAGM Statement
17th Jun 20135:01 pmRNSHolding(s) in Company
12th Jun 201310:08 amRNSBoard Changes
5th Jun 20137:00 amRNSPosting of Annual Report and Notice of AGM
20th May 20137:00 amRNSCompletion of US$15m Convertible Bond Issue
8th May 20137:00 amRNSSuccessful Arrangement of US$15m Convertible Bond
7th May 20137:00 amRNSFinal Results
2nd May 20137:00 amRNSChange in Reporting Currency
29th Apr 20137:47 amRNSNotice of Final Results
29th Apr 20137:00 amRNSAtlantis Water Project Update
17th Apr 20137:00 amRNSHolding(s) in Company
15th Apr 20137:00 amRNSBoard Update
3rd Apr 20135:30 pmRNSHolding(s) in Company
28th Mar 20137:55 amRNSAtlantis Water Project
27th Mar 20134:09 pmRNSHolding(s) in Company
11th Mar 20135:19 pmRNSHolding(s) in Company
7th Mar 20137:00 amRNSOperational Update
11th Feb 20131:34 pmRNSHolding(s) in Company
16th Jan 20137:00 amRNSHolding(s) in Company
14th Jan 20137:00 amRNSAppointment of Non-Executive Director
11th Jan 20137:00 amRNSCommissioning of IO#2 IOsorbT Plant
20th Dec 20128:12 amRNSHolding(s) in Company
18th Dec 20129:00 amRNSHolding(s) in Company
4th Dec 20127:00 amRNSProduction Update
17th Sep 20127:00 amRNSHalf Yearly Report
6th Sep 20127:00 amRNSNotice of Results
16th Aug 20127:00 amRNSCommissioning of Plant
31st Jul 20127:00 amRNSCompletion of Construction of IO#1 IOsorb Plant
20th Jun 20122:25 pmRNSResult of AGM
20th Jun 20127:00 amRNSPurchase of Iodine Extraction Facility
7th Jun 20127:00 amRNSHolding(s) in Company
25th May 20127:00 amRNSFinal Results
25th May 20127:00 amRNSPlacing to raise £4.3 million
19th Apr 20127:56 amRNSAppointment of Investec as Nomad and Sole Broker
10th Apr 20129:39 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.